Market Research Reports :According to a new market report published by Transparency Market Research “China Osteoporosis Market - Industry Analysis, Size, Share, Growth, Trends And Forecast, 2012 – 2018" The Chinese Osteoporosis drug market is expected to grow at a CAGR of 14.4% from 2007 to 2018. Increased prevalence of Osteoporosis among Chinese female population is the principal growth driver of the Osteoporosis drug industry. The other key growth drivers for the Chinese Osteoporosis market include increasing elderly aged population, rising living standards of the Chinese people and increasing awareness and bone health education. Browse the full report at : http://www.transparencymarketresearch.com/china-osteoporosis-market.html

1. REPORT DESCRIPTION
Chinese Osteoporosis drug market is expected to grow at a CAGR of 14.4% from
2012 to 2018. : Transparency Market Research
Market Research Reports :According to a new market report published by Transparency
Market Research “China Osteoporosis Market - Industry Analysis, Size, Share, Growth,
Trends And Forecast, 2012 – 2018" The Chinese Osteoporosis drug market is expected to
grow at a CAGR of 14.4% from 2007 to 2018.
Increased prevalence of Osteoporosis among Chinese female population is the principal
growth driver of the Osteoporosis drug industry. The other key growth drivers for the
Chinese Osteoporosis market include increasing elderly aged population, rising living
standards of the Chinese people and increasing awareness and bone health education.
Geographical analysis of Chinese Osteoporosis drug Industry shows that there is a huge
growth potential for Osteoporosis drugs in many cities including Shanghai, Beijing,
Guangzhou, and Hangzhou.
Bisphosphonate is the leading Osteoporosis drug class in China for Osteoporosis treatment
and is expected to remain so for the next few years.
To gain competitive advantage, market players should develop cost-competitive drugs with
easy dosage patterns, which promote bone building effectively.
Transparency Market Research
China Osteoporosis Market
- Industry Analysis, Size,
Share, Growth, Trends And
Forecast, 2012 – 2018
Single User License: US $ 1500
Multi User License: US $ 2500
Corporate User License: US $ 3500
Buy Now
Request Sample
Published Date: July 2013
28 Pages Report

2. Browse Report : Osteoporosis market
Large numbers of patients are unable to comply with the strict dosage schedule of
traditional Osteoporosis drugs. Further research and development can address unmet needs
by coming up with drugs that have a convenient dosage schedule with better efficacy and
safety compared to traditional treatment of Osteoporosis.
After 2012, the Parathyroid Hormone and SERM Osteoporosis drug class industry is
expected to decline because of anticipated growth of Prolia (Denosumab), which will eat
away other drugs’ market share.
TABLE OF CONTENTS
1. Executive Summary
2. China Osteoporosis Market
2.1. Market Overview
2.2. Growth Drivers and Opportunities
2.3. Recent Market Developments
2.4. Competitive Strategies
2.5. Future Outlook
2.6. Driving Factor Analysis of China Osteoporosis Market
2.6.1. Demand Side Drivers
2.6.2. Supply Side Drivers
2.6.3. Restraints
2.6.4. Opportunities
2.6.5. Key Competitive Points
3. China Osteoporosis Market Share (2012 - 2018)
3.1. By Drug Class - Osteoporosis Market Share & Forecast
3.2. By Drug Market Share - Osteoporosis Market Share & Forecast

3. 4. Osteoporosis Drugs Classes Market & Forecast (2012 - 2018)
4.1. China Bisphosphonate Market & Forecast
4.2. China Selective Estrogen Receptor Modulators (SERM) Market & Forecast
4.3. China Parathyroid Hormone (PTH) Market & Forecast
4.4. China Calcitonin Market & Forecast
Browse Report : http://www.transparencymarketresearch.com/china-
osteoporosis-market.html
5. Osteoporosis Drugs Market Analysis & Forecast (2012 - 2018)
5.1. Bisphosphonate Drugs Market Analysis
5.1.1. Fosamax (Alendronate)
5.1.2. Bonviva/Boniva (Ibandronic Acid)
5.1.3. Reclast/Aclasta
5.1.4. Actonel (Risedronate)
5.2. SERMs Drugs Market Analysis
5.2.1. Evista (Raloxifene)
5.2.2. Viviant/ Conbriza (Bazedoxifene)
5.3. Parathyroid Hormone Drugs Market Analysis
5.3.1. Forteo
5.4. Calcitonin Drugs Market Analysis
5.4.1. Miacalcin
5.5. Prolia (Denosumab)
6. Pipeline Drugs in Osteoporosis Market Analysis
6.1. Odanacatib (MK 0822)
6.2. Aprela (Bazedoxifene)

4. 7. Recommendations
7.1. Market Strategy for Success
7.2. Barriers to be Considered
7.3. Future
About Us:
Transparency Market Research is a market intelligence company providing global business
information reports and services. Our exclusive blend of quantitative forecasting and trends
analysis provides forward-looking insight for thousands of decision makers.
We are privileged with highly experienced team of Analysts, Researchers and Consultants,
who use proprietary data sources and various tools and techniques to gather, and analyze
information. Our business offerings represent the latest and the most reliable information
indispensable for businesses to sustain a competitive edge.
Contact:
Transparency Market Research
90 State Street,
Suite 700,
Albany
NY - 12207
United States
Tel: +1-518-618-1030
USA - Canada Toll Free 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com/